Drugdu.com expert's response:

In pharmaceutical foreign trade inquiries, many communications start off very lightly. Buyers first ask if the product is available, then review the COA, specifications, and price, and sometimes request samples. At this stage, suppliers are mostly confirming product compatibility, while buyers are still screening options.

However, when the conversation progresses to the point where buyers start asking about annual purchase volumes, long-term pricing, and stable supply capabilities, the situation changes.

For example, if a buyer begins to inquire about how much goods they will need in a year, whether quarterly deliveries are possible, and if prices can be recalculated for long-term cooperation, such questions usually indicate that they are no longer just considering "whether they can make a single purchase" — they are assessing whether the supplier can be included in their long-term cooperation network.

Of course, this does not mean an order will be placed immediately. Many buyers at this stage are still in the process of supplier screening, price calculation, annual budget planning, or alternative supplier evaluation. If suppliers only see "large quantities" and "long-term procurement" and immediately slash prices to the lowest level, they will easily find themselves in a passive position later.

Annual purchase volume sounds like a very clear number, but in actual communication, it can represent many different scenarios. Some are the real usage volumes from the buyer's existing projects, some are estimated demands given by end customers, some are just roughly calculated quantities by traders based on market conditions, and some customers will use a relatively large annual demand to secure better prices without having clear orders in the short term.

Therefore, when seeing an annual purchase volume, do not only focus on the total number. What is more worthy of attention is where this demand comes from and how the buyer plans to make the purchases later. For example, if the requirement is several tons a year, will it be purchased in one go or shipped in batches? Will it be fixed quarterly procurement or orders placed according to project progress? Is there a requirement for the same production source, consistent quality standards, and stable supply across consecutive batches? Without clarifying this information, the annual purchase volume is just a reference and cannot be directly equated to a real order.

The same applies to long-term pricing. The price of pharmaceutical products is rarely determined solely by "long cooperation time". Specifications, quality standards, procurement frequency, packaging methods, delivery rhythms, payment terms, and document support all affect the final price. This is especially true for APIs, excipients, and peptide drug substances. The quotation logic for samples, small trial orders, commercial batches, and annual agreement prices are not the same.

If suppliers offer the so-called long-term low price prematurely, they may encounter several problems later: the buyer finally only places a small batch order but expects the annual price to apply; what was said to be long-term procurement actually results in very small quantities each time; later, additional requirements for quality documents, registration support, fixed batches, etc. are added, but the previous price did not cover these costs.

When a buyer asks about annual production capacity, it cannot simply be understood as them wanting to hear a number. Very often, they are judging supply stability. Especially for buyers who plan to make long-term purchases, they will care about whether the supplier can continuously provide products with the same quality standards, whether commercial batches are stable, whether delivery times are controllable, and whether subsequent documents can be supported in the long run. For buyers, the production capacity figure is one aspect, but being able to deliver stably according to their procurement rhythm is a more practical concern.

If this type of inquiry moves forward, the subsequent discussions will usually not only focus on price. The buyer may continue to review the COA of the latest batches, specifications, GMP documents, manufacturer information, stability data, DMF status, send out supplier questionnaires, or even propose audit requirements. At this point, the inquiry is no longer a simple price check — it is moving in the direction of supplier qualification assessment.

Therefore, when a buyer starts asking about annual purchase volumes and long-term pricing, it is usually a noteworthy signal. It indicates that the other party may have included the supplier in the candidate list for long-term cooperation. However, the quality of such inquiries cannot be judged solely by "large quantities". The clients that are truly worth continuing to invest in are those who are willing to gradually clarify their procurement background, target markets, quality standards, procurement rhythms, and document requirements.

If a buyer only repeatedly emphasizes "large-volume procurement", "long-term cooperation", and "give the lowest price" but is unwilling to specify the product application, procurement frequency, target market, and project stage, then this lead may still be in the price probing stage. Suppliers can maintain communication, but there is no need to give away prices, production capacity, or other cooperation conditions prematurely.

Long-term cooperation in pharmaceutical foreign trade rarely goes directly from a sentence of "long-term price" to an order. It is usually advanced step by step: first confirm the product, then confirm the quality standards, review samples and documents, and only then enter discussions on annual purchase volumes, price cycles, delivery rhythms, and supplier audits.

Only when the buyer is willing to discuss these issues in detail does it mean that the inquiry is moving towards long-term procurement. For suppliers, the most important thing at this stage is not to rush to offer the lowest price, but to judge whether the other party's annual demand is real, whether the procurement rhythm is clear, and whether the document and quality requirements can be met. Only when this information gradually becomes clear can the long-term price be discussed on a solid basis.